URGN
UroGen Pharma Ltd.Company Information
- Company Name
- UroGen Pharma Ltd.
- CIK
- CIK0001668243
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- URGN: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- URGN
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-09-08
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 127,735
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 40,349,691
- Shares outstanding
- 50,380,112
- Ownership
- 80.09%
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- -6.05%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Cash Equivalents At Carrying Value | 79 | 110 | 111 | 90 | 93 | 104 | 172 | 125 | 220 | 131 | 95 | 119 | ||||||
| Available For Sale Securities Debt Securities Current | 29 | 30 | 10 | 37 | 64 | 92 | 65 | 125 | 21 | 33 | 42 | 28 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 235 | 237 | 186 | 169 | 197 | 237 | 276 | 295 | 279 | 197 | 169 | 182 | ||||||
| Restricted Cash Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Accounts Receivable Net Current | 89 | 55 | 33 | 20 | 20 | 20 | 20 | 23 | 17 | 14 | 15 | 13 | ||||||
| Inventory Net | 25 | 21 | 16 | 8 | 7 | 8 | 9 | 8 | 7 | 7 | 6 | 5 | ||||||
| Prepaid Expense And Other Assets Current | 13 | 20 | 15 | 12 | 12 | 13 | 9 | 14 | 12 | 10 | 10 | 16 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Restricted Investments Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Available For Sale Securities Debt Securities Noncurrent | - | - | 0 | 0 | 5 | 5 | 5 | 5 | 0 | 0 | 5 | 7 | ||||||
| Finance Lease Right Of Use Asset | 5 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Right Of Use Asset | 3 | - | - | - | - | - | - | 1 | 1 | 1 | 2 | 2 | ||||||
| Other Assets Noncurrent | 9 | 7 | 5 | 7 | 1 | 0 | 1 | 0 | 1 | 1 | 2 | 2 | ||||||
| Assets | 253 | 254 | 200 | 185 | 209 | 248 | 286 | 302 | 282 | 201 | 178 | 194 | ||||||
| Accounts Payable And Accrued Liabilities Current | 40 | 35 | 28 | 26 | 31 | 30 | 27 | 20 | 24 | 18 | 17 | 14 | ||||||
| Employee Related Liabilities Current | 12 | 10 | 14 | 11 | 12 | 7 | 11 | 9 | 7 | 5 | 11 | 8 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 62 | 51 | 46 | 42 | 48 | 42 | 46 | 33 | 34 | 26 | 31 | 26 | ||||||
| Finance Lease Liability Current | 1 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Current | 1 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Other Liabilities Current | 8 | 5 | 5 | 5 | 5 | 5 | 8 | 4 | 4 | 3 | 4 | 4 | ||||||
| Long Term Debt Noncurrent | 189 | 190 | 122 | 122 | 123 | 122 | 122 | 122 | 98 | 98 | 99 | 99 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Finance Lease Liability Noncurrent | 3 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 2 | - | - | - | - | - | - | 0 | 0 | 1 | 1 | 1 | ||||||
| Liability For Uncertain Tax Positions Noncurrent | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | ||||||
| Liabilities | 385 | 378 | 306 | 300 | 302 | 294 | 295 | 276 | 252 | 241 | 244 | 236 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 865 | 859 | 854 | 818 | 806 | 803 | 797 | 794 | 775 | 671 | 614 | 611 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | -132 | -124 | -105 | -115 | -93 | -46 | -9 | 26 | 30 | -40 | -65 | -42 | ||||||
| Retained Earnings Accumulated Deficit | -998 | -983 | -960 | -933 | -900 | -850 | -806 | -769 | -745 | -712 | -679 | -653 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | 0 | -0 | ||||||
| Liabilities And Stockholders Equity | 253 | 254 | 200 | 185 | 209 | 248 | 286 | 302 | 282 | 201 | 178 | 194 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 49 | 49 | 48 | 47 | 46 | 46 | 42 | 42 | 41 | 36 | 32 | 31 | ||||||
| Shares Outstanding | 49 | 49 | 48 | 47 | 46 | 46 | 42 | 42 | 41 | 36 | 32 | 42 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialUroGen Pharma Ltd. (URGN) — SEC Financial Statements & Analysis
UroGen Pharma Ltd. (URGN) is a pharmaceutical preparations company, incorporated in L3. UroGen Pharma Ltd. trades on Nasdaq as: URGN. UroGen Pharma Ltd. (URGN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, UroGen Pharma Ltd. carries a market cap of $1.85B, a P/E ratio of -18.99x, a P/B ratio of -14.00x, a P/S ratio of 9.82x, an enterprise value of $1.97B, and an EV/EBITDA multiple of -29.62x. On profitability, it posts a gross margin of 90.85%, an operating margin of -35.32%, a net margin of -51.73%, a Return on Equity (ROE) of 86.49%, and a Return on Assets (ROA) of -42.33%. Per share, it reports EPS of $-1.94, free cash flow per share of $-3.16, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 100.27% year-over-year, net income growth of -37.00% year-over-year, and EPS growth of -40.30% year-over-year. On the balance sheet, it maintains a current ratio of 3.80x, a quick ratio of 3.20x, working capital of $173.51M, a debt-to-equity ratio of -2.91x, a debt ratio of 1.52, an interest coverage ratio of -4.11x, free cash flow of $-159.13M (TTM), and net debt of $111.01M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.85B
- P/E TTM
- -18.99x
- EPS TTM
- $-1.94
- P/B TTM
- -14.00x
- ROE TTM
- 86.49%
- ROA TTM
- -42.33%
- Debt To Equity
- -2.91x
- Free Cash Flow TTM
- $-159.13M
- Net Revenue TTM Growth 1Y
- 100.27%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is UroGen Pharma Ltd. in?
UroGen Pharma Ltd. (URGN) operates in the Pharmaceutical Preparations industry.
What exchange does URGN trade on?
UroGen Pharma Ltd. (URGN) trades on the Nasdaq.
Where is UroGen Pharma Ltd. incorporated?
UroGen Pharma Ltd. is incorporated in Israel.
When was UroGen Pharma Ltd. (URGN)'s most recent SEC filing?
UroGen Pharma Ltd. (URGN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is URGN's market cap?
UroGen Pharma Ltd. (URGN) has a market capitalization of $1.85B as of 2026-06-30.
What is URGN's EPS (earnings per share)?
UroGen Pharma Ltd. (URGN)'s trailing twelve month EPS is $-1.94 as of 2026-06-30.
What is URGN's ROE (return on equity)?
UroGen Pharma Ltd. (URGN)'s trailing twelve month Return on Equity (ROE) is 86.49% as of 2026-06-30.
What is URGN's ROA (return on assets)?
UroGen Pharma Ltd. (URGN)'s trailing twelve month Return on Assets (ROA) is -42.33% as of 2026-06-30.
What is URGN's EV/EBITDA?
UroGen Pharma Ltd. (URGN)'s trailing twelve month EV/EBITDA is -29.62x as of 2026-06-30.